Skip to content
    Westlake Village BioPartners logo

    Westlake Village BioPartners

    Westlake Village, United StatesFounded 2018
    westlakebio.comLinkedIn
    Biotech & Life SciencesHealthcare

    Westlake Village BioPartners is a people-first life science venture capital firm that incubates and builds biotech companies by pairing world-class entrepreneurs with hands-on support and capital from ideation through commercial impact.

    46% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (46% of deals). Average disclosed round size is $116.7M (across 26 rounds with reported amounts).

    Find people at Westlake Village BioPartners on Goldilocks AI

    Portfolio

    18

    Fund Size

    $450M

    Top Stage

    Series A

    Last 12 Mo

    0

    Team

    Beth Seidenberg, MD

    Beth Seidenberg, MD

    Founding Managing Director

    David Allison, PhD

    David Allison, PhD

    Managing Director

    Mira Chaurushiya, PhD

    Mira Chaurushiya, PhD

    Managing Director

    Desmond Padhi, PharmD

    Desmond Padhi, PharmD

    Operating Partner

    Kelli McKeirnan

    Kelli McKeirnan

    Director of Administration

    Brogan Perrelli, CPA

    Brogan Perrelli, CPA

    VP of Finance and Operations

    Lauren Popov, PhD

    Lauren Popov, PhD

    Associate

    Armando Alvarez, CPA

    Armando Alvarez, CPA

    Finance Manager

    Jennifer Kercher, JD

    Jennifer Kercher, JD

    General Counsel

    BS

    Beth Seidenberg

    Founding Managing Director

    SH

    Sean Harper

    Co-founding Managing Director

    MC

    Mira Chaurushiya

    Managing Director

    Portfolio Breakdown

    Stage Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    28 investments
    CompanyRoundAmountDate
    AllRock logoAllRockSeries A$50MSep 2025
    Latigo Biotherapeutics logoLatigo BiotherapeuticsSeries B$150MMar 2025
    Star Therapeutics logoStar TherapeuticsSeries D$125MJan 2025
    ArsenalBio logoArsenalBioSeries C$325MSep 2024
    Latigo Biotherapeutics logoLatigo BiotherapeuticsSeries A$135MFeb 2024
    AArsenal BiosciencesSeries C$325MJan 2024
    KKyverna TherapeuticsSeries B$60MAug 2023
    Kate logoKateSeries A$51MJun 2023
    KKate TherapeuticsSeries A$51MJun 2023
    DDantariSeries A$47MDec 2022
    AAcelyrin, IncSeries C$300MSep 2022
    AArsenal BiosciencesSeries B$220MSep 2022
    EElectra TherapeuticsSeries B$84MFeb 2022
    Kyverna logoKyvernaSeries B$85MJan 2022
    AArsenal BioSeries B$220MJan 2022
    Capsida logoCapsidaSeries A$50MApr 2021
    CCapsida BiotherapeuticsSeries A$140MApr 2021
    Neuron23 Inc logoNeuron23 IncSeries B$113.5MDec 2020
    KKyverna TherapeuticsSeries A$25MJan 2020
    AAcelyrin, IncSeries A—Jan 2020
    Kyverna logoKyvernaSeries A$25MJan 2020
    Tmunity logoTmunitySeries B$75MOct 2019
    ArsenalBio logoArsenalBioSeries A$85MOct 2019
    EExpansion TherapeuticsSeries A$80MJan 2018
    Neuron23 Inc logoNeuron23 IncSeries C$100M—
    Page 1 of 2

    Top Co-Investors

    Kleiner Perkins10 shared
    Cowen Healthcare Investments5 shared
    Surveyor Capital5 shared
    Versant Ventures5 shared
    Cormorant Asset Management5 shared
    OrbiMed5 shared
    Sanofi Ventures4 shared
    Gilead Sciences4 shared
    Hitachi Ventures4 shared
    Bristol Myers Squibb4 shared
    Redmile Group3 shared
    HBM Healthcare Investments3 shared
    Blue Owl Capital3 shared
    Alexandria Venture Investments3 shared
    Access Biotechnology3 shared
    Rock Springs Capital3 shared
    Northpond Ventures3 shared
    RA Capital Management3 shared
    AbbVie2 shared
    Foresite Capital2 shared

    Last updated: 20 October 2026